Plain-English translation of NCT06158126 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is comparing two different ways to take HIV prevention medicine during pregnancy: a daily pill and a monthly injection called cabotegravir (CAB-LA). Researchers want to understand whether these medications are safe for pregnant women and their babies, and how they affect pregnancy outcomes like miscarriage, stillbirth, and infant health.
Many pregnant women need HIV prevention, but doctors don't have enough information about how the newer long-acting injectable medication affects pregnancy and infant health compared to the daily pill. This study will help provide that safety information so doctors and patients can make informed choices.
You likely qualify if…
You likely don't qualify if…
You will choose either a daily pill or a monthly injection for HIV prevention and continue it throughout your pregnancy. You'll visit the clinic regularly following the standard pregnancy care schedule, plus additional visits for safety monitoring—during pregnancy, at delivery, and for up to one year after your baby is born. At each visit, you'll have clinical exams and blood tests to check on your health and your baby's health.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
Malawi